3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
4
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
4
Myeloid
2
Tumor-Agnostic
1
Other hematologic neoplasm
1
Genitourinary
1
Gastrointestinal
1
Conditions
Melanoma
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
164
Prednisone
130
enzalutamide
127
Docetaxel
122
Abiraterone Acetate
95
Nivolumab
93
Gemcitabine
71
Sunitinib
67
atezolizumab
50
abiraterone
50
Leuprolide
49
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
48
Cisplatin
48
radium Ra 223 dichloride
39
Sorafenib
39
darolutamide
38
apalutamide
38
Ipilimumab
38
Carboplatin
37
Prednisolone
33
Everolimus
33
Axitinib
32
cabozantinib
31
avelumab
31
pazopanib
30
Bevacizumab
30
Paclitaxel
29
enfortumab vedotin
28
bicalutamide
28
Cyclophosphamide
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
peginterferon alfa-2b
×
Genitourinary
×
Clear all
NCT02089685
2022-09-13
MK-3475-029
Merck Sharp & Dohme LLC
Phase 1/2
Completed
295 enrolled
25 charts